Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Flumazenil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 known ✓ | P18507 | 16/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 16/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 16/20 | 1.00 |
| ▸ | GABRA1 known ✓ | P14867 | 15/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 14/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 14/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 10/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 8/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumazenil SCHEMBL29746432 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL5781309 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29444064 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL11885881 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL30305657 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL16187025 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL12484498 | 0.99 | GABRG2 (0.98) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29085132 | 0.97 | GABRG2 (0.94) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29025825 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL16479000 | 0.92 | GABRG2 (0.85) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7815 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102405-A1 | COMPOSITIONS COMPRISING FLUMAZENIL AND NALTREXONE AND METHODS FOR USE THEREOF | Trexapharm Pty Ltd (AU) | 2026-04-16 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260062760-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-03-05 | — | — | US | claimed |
| US-20260055473-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF MULTIPLE MYELOMA PROGRESSION | MOREHOUSE SCHOOL OF MEDICINE (US) | 2026-02-26 | — | — | US | claimed |
| US-12521401-B2 | Compositions comprising flumazenil and naltrexone and methods for use thereof | Trexapharm Pty Ltd (AU) | 2026-01-13 | — | — | US | claimed |
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-5670640-A | CHEMICAL CONDENSATION AND CYCLIZATION USING ALKYLLITHIUM, ALKOXIDES, LITHIUM HEXAMETHYLDISILAZIDE | HOFFMANN-LA ROCHE INC. (US) | 1997-09-23 | — | — | US | claimed |
| EP-0639275-B1 | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES | NEUROGEN CORP (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0787729-A2 | A process for the manufacture of imidazodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | claimed |
| US-5580574-A | INCLUDING A BENZODIAZEPINE ANTAGONIST TO OVERCOME THE SEDATIVE EFFECTS OF THE BENZODIAZEPINE ACTIVE INGREDIENT | HOFFMANN-LA ROCHE INC. (US) | 1996-12-03 | — | — | US | claimed |
| US-5552153-A | BENZODIAZEPINES AND ANTAGONISTS | HOFFMAN-LA ROCHE INC. (US) | 1996-09-03 | — | — | US | claimed |
| WO-1995029678-A1 | PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 1995-11-09 | — | — | WO | claimed |
| CN-1110135-A | Pharmaceutical composition for controlled release | HOFFMANN LA ROCHE (CH) | 1995-10-18 | — | — | CN | claimed |
| EP-0662322-A2 | Pharmaceutical composition for controlled release | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-12 | — | — | EP | claimed |
| US-5244900-A | Imidazo-benzodiazepines, imidazo-thiophenediazepines, treatment of cerebrovascular seizures | HOFFMANN-LA ROCHE INC. (US) | 1993-09-14 | — | — | US | claimed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |